SUBSCRIBE
SUBSCRIBE

Spinal muscular atrophy

Bookmark and Share
Pharm Country
Drug Candidate For Treating Spinal Muscular Atrophy Identified at Cold Spring Harbor Laboratory
November 9, 2009
 · 
1 min read
Bookmark and Share
BioMidwest
Possible Treatment For Spinal Muscular Atrophy, Iowa State University Study
July 31, 2009
 · 
1 min read
BioMidwest
University of Wisconsin-Madison Scientists Find Potent New Weapon To Fight Spinal Muscular Atrophy
December 22, 2008
 · 
1 min read
BioMidwest
National Institutes of Health (NIH): Treatment Extends Survival In Mouse Model Of Spinal Muscular Atrophy
February 23, 2007
 · 
1 min read
Load More
PRESS RELEASES
Press Releases
Dubai’s Medcare Hospital Becomes the World’s First to Treat an Adult Spinal Muscular Atrophy (SMA) Patient Outside the US
April 28, 2026
 · 
2 min read
Press Releases
Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA)
April 24, 2026
 · 
8 min read
Press Releases
Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)
March 31, 2026
 · 
9 min read
Press Releases
FDA Approves High Dose Regimen of SPINRAZA® for Spinal Muscular Atrophy, Reflecting Progress Made Possible Through Decades of MDA Supported Research
March 30, 2026
 · 
4 min read
Press Releases
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
March 30, 2026
 · 
13 min read
Press Releases
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy
March 11, 2026
 · 
12 min read
Press Releases
Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
March 9, 2026
 · 
16 min read
Press Releases
GEMMABio Announces First Patient Dosed in CHARISMA Trial of GB221, Investigational Next‑Generation Gene Therapy for Spinal Muscular Atrophy Type 1 (SMA1)
February 26, 2026
 · 
5 min read
Press Releases
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
February 4, 2026
 · 
10 min read
Press Releases
NMD Pharma announces topline results from its Phase 2a study of ignaseclant in Charcot-Marie-Tooth disease Types 1 and 2
February 3, 2026
 · 
10 min read
Press Releases
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
January 13, 2026
 · 
13 min read
Press Releases
Orsini Selected as Specialty Pharmacy Partner for ITVISMA® (onasemnogene abeparvovec-brve)
December 3, 2025
 · 
2 min read
Press Releases
Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)
November 25, 2025
 · 
8 min read
Press Releases
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
November 17, 2025
 · 
13 min read
Press Releases
FDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)
February 13, 2025
 · 
7 min read
Press Releases
FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)
February 13, 2025
 · 
9 min read
Press Releases
FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
January 23, 2025
 · 
7 min read
Press Releases
Majority of Children With Spinal Muscular Atrophy (SMA) Treated With Genentech’s Evrysdi Are Able to Sit, Stand and Walk Independently, Two-Year Data Demonstrate
October 14, 2024
 · 
10 min read
Press Releases
Majority of children with spinal muscular atrophy (SMA) treated with Roche’s Evrysdi are able to sit, stand and walk independently, two-year data demonstrate
October 14, 2024
 · 
8 min read
Press Releases
Spinal Muscular Atrophy Market Size to Reach US$ 13.0 Billion by 2034, Impelled by Increased Popularity of Gene Therapy
July 17, 2024
 · 
12 min read
Load More